Skip to main content

Endophthalmitis

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Santen
SantenCA - Emeryville
2 programs
CefuroximeN/A1 trial
Levofloxacin Ophthalmic SolutionPHASE_1_21 trial
Active Trials
NCT00136344Completed35,000Est. May 2006
NCT04214821Unknown128Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SantenLevofloxacin Ophthalmic Solution
SantenCefuroxime

Clinical Trials (2)

Total enrollment: 35,128 patients across 2 trials

NCT04214821SantenLevofloxacin Ophthalmic Solution

The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

Start: Sep 2019Est. completion: May 2022128 patients
Phase 1/2Unknown

Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery

Start: Sep 2003Est. completion: May 200635,000 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.